MNPR-101
Advanced cancers (e.g., pancreatic, triple-negative breast cancer)
PreclinicalActive
Key Facts
Indication
Advanced cancers (e.g., pancreatic, triple-negative breast cancer)
Phase
Preclinical
Status
Active
Company
About Monopar Therapeutics
Monopar Therapeutics is a publicly traded biotech company (NASDAQ: MNPR) advancing a pipeline of novel oncology candidates. Its most advanced asset, Validive (clonidine HCl mucoadhesive buccal tablet), is designed to prevent a debilitating side effect of cancer treatment and has received Fast Track and Orphan Drug designations from the FDA. The company's strategy centers on developing targeted therapies for underserved oncology indications with high unmet medical need.
View full company profile